Clinical Trials Logo

Multiple Myeloma clinical trials

View clinical trials related to Multiple Myeloma.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03955900 Not yet recruiting - Multiple Myeloma Clinical Trials

A Registry Study of Participants With Multiple Myeloma in Latin America

MYLACRE
Start date: May 17, 2019
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to characterize the multiple myeloma (MM) population concerning demographics and clinical characteristics (for example. frailty, risk strata, manifestations of target organ damage [TOD]) in 6 countries (that is Argentina, Brazil, Mexico, Chile, Colombia and Panama); and to profile the treatment landscape of Latin American MM participants, including factors associated with health-care provider (HCP) selections of different treatment regimens. These factors can include a participant's demographic and clinical characteristics and availability of different therapy options per institution in each country.

NCT ID: NCT03952832 Not yet recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma

Start date: June 11, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well leflunomide works in treating patients with high-risk smoldering multiple myeloma. Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03946332 Not yet recruiting - Multiple Myeloma Clinical Trials

Physical Activity for Myeloma Autograft Longitudinal Study

PAMAL
Start date: May 2019
Phase: N/A
Study type: Interventional

Physical exercises program is known to improve quality of life, chronical fatigue and appears to be a behavioural recommendation against cancer as primary and tertiary prevention. Nutritional status is also important in cancer patients: a loss of 5% of weight increases the complication risks and decreases survival and the quality of life. Interactions between physical activity and haematological malignancies are less described compared to solid cancers. Methodology and protocols are also heterogeneous. Supervised exercises program improves the physical condition and the quality of life; however there are few randomised studies versus a controlled group. Post autograft evaluation for myeloma patients showed a physical deficit with increased fat mass, but in this particular population physical exercises need to be more explored. This project is a randomised study versus controlled group that evaluates supervised physical exercises program in a homogenous population: patients under-65-years-old with multiple myeloma and who will undergo autologous stem cell transplantation.

NCT ID: NCT03944057 Not yet recruiting - Clinical trials for Multiple Myeloma in Relapse

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma

MARCH
Start date: June 1, 2019
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm study of ATG-010 (selinexor) plus low-dose Dexamethasone (Sd) in patients with multiple myeloma previously treated with lenalidomide and bortezomib refractory to prior treatment with immunomodulatory agents and proteasome Inhibitors.

NCT ID: NCT03943472 Not yet recruiting - Multiple Myeloma Clinical Trials

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

Start date: May 2019
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to study the feasibility and efficacy of anti-B-Cell Maturation Antigen (BCMA) expressing T cells in treating patients with multiple myeloma.

NCT ID: NCT03942224 Not yet recruiting - Plasma Cell Myeloma Clinical Trials

Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma

DeRIVE
Start date: May 1, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well daratumumab, ixazomib, and dexamethasone with or without bortezomib work in treating patients with newly diagnosed multiple myeloma. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as ixazomib, dexamethasone, and bortezomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving daratumumab, ixazomib, and dexamethasone with or without bortezomib may work better in treating patients with multiple myeloma.

NCT ID: NCT03941860 Not yet recruiting - Plasma Cell Myeloma Clinical Trials

Lenalidomide With or Without Ixazomib in Treating Patients With Evidence of Residual Multiple Myeloma After Stem Cell Transplant

Start date: May 29, 2019
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplant. Immunotherapy with lenalidomide may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplant.

NCT ID: NCT03934684 Not yet recruiting - Clinical trials for Relapsed Refractory Multiple Myeloma

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Start date: July 28, 2019
Phase: Phase 4
Study type: Interventional

To characterize safety associated with the use of Kyprolis under the locally approved label.

NCT ID: NCT03933735 Not yet recruiting - Multiple Myeloma Clinical Trials

A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma

Start date: May 2019
Phase: Phase 1
Study type: Interventional

This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory MM who have received at least 3 prior lines of therapy. The study consists of 2 portions, a monotherapy dose escalation (Arm A) and a monotherapy dose expansion (Arm B). Arm A will evaluate the safety, tolerability, PK and PD profiles of escalating doses of single-agent TNB-383B ranging from 25 micrograms to 40 milligrams per dose, administered once every 3 weeks (Q3W), in approximately 24 subjects. Once the maximum tolerated dose (MTD) or recommended phase 2 dose, (RP2D) is identified in Arm A, Arm B will be initiated to further characterize the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the MTD/RP2D dose of TNB 383B monotherapy in approximately 48 subjects.

NCT ID: NCT03915184 Not yet recruiting - Multiple Myeloma Clinical Trials

Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma

Start date: August 1, 2019
Phase: Phase 1
Study type: Interventional

A phase 1b, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.